MB
| Title | Published in | Access level | OA Policy | Year | Views | Downloads | |
|---|---|---|---|---|---|---|---|
| Primary and Acquired Resistance to Immunotherapy with Checkpoint Inhibitors in NSCLC : From Bedside to Bench and Back | BioDrugs |  | 2025 | 47 | 226 | ||
| Unveiling the landscape of uncommon EGFR mutations in NSCLC-A systematic review | Journal of thoracic oncology | | 2024 | 144 | 560 | ||
| Management of stage III non-small-cell lung cancer : rays of hope | Exploration of targeted anti-tumor therapy | | 2024 | 62 | 71 | ||
| Decoding the Clinical and Molecular Signatures of EGFR Common, Compound, and Uncommon Mutations in NSCLC : A Brief Report | Journal of thoracic oncology | | 2024 | 37 | 14 | ||
| Rates of febrile neutropenia and its causes in the real world | Future oncology | | 2024 | 22 | 65 | ||
| Bringing immune-checkpoint inhibitors earlier in the management of non-small cell lung cancer | Translational lung cancer research | | 2023 | 85 | 24 | ||
| The evolving role of immune-checkpoint inhibitors in malignant pleural mesothelioma | Journal of clinical medicine | | 2023 | 45 | 59 | ||
| Novel targets for immune-checkpoint inhibition in cancer | Cancer treatment reviews | | 2023 | 89 | 52 |
